Shamburg News · 8-K filed Nov 13, 2026, 7:20 AM EST

Jade Biosciences Reports Third Quarter 2026 Results; Net Loss of $35.1 Million

JBIO · Jade Biosciences, Inc.

  • Earnings
  • Materiality: high

Jade Biosciences reported financial results for the quarter ended September 30, 2026, in a press release furnished as Exhibit 99.1. The company reported a net loss of $35.1 million for the quarter, compared with $25.2 million a year earlier, and cash, cash equivalents and investments of $475.7 million as of September 30, 2026. The company said it expects to initiate the Phase 3 EVERGREEN trial of JADE101 in the fourth quarter of 2026 and that its cash provides runway into the fourth quarter of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-459287.

Written from the filing by Shamburg Markets. Figures are as reported by the company.